PRESS RELEASES

- October 27 2020 2020 half-year results
- September 9 2020 Launch of MISTI, a modular platform for instruments
- July 23 2020 Publication of a clinical study on the advantages of Mont-Blanc 3D+ in the treatment of scoliosis
- July 9 2020 Revenue for the first half of 2020
- May 29 2020 Minutes of the Extraordinary and Ordinary General Shareholders’ Meeting of 26 May 2020 Capital decrease
- May 23 2020 Government-backed loan of €1.13M secured / Reserved capital increase of €4.6M implemented
- April 23 2020 Signature of an exclusive agreement with the Japanese distributor MURANAKA Medical Instruments
- April 16 2020 2019 annual results
- January 29 2020 Appointment of Myriam Denis-Galland as Chief Financial Officer
- January 16 2020 2019 : a year of restructuring 2019 revenue of €5M
- December 30 2019  Erratum : First subscription phase pursuant to the agreement for the issue of tranche warrants granting rights to exercise bonds convertible into new ordinary shares with warrants entered into with NEGMA GROUP LTD on 16 October 2019
- December 26 2019  First subscription phase pursuant to the agreement for the issue of tranche warrants granting rights to exercise bonds convertible into new ordinary shares with warrants entered into with NEGMA GROUP LTD on 16 October 2019
- November 4 2019 Patent issued in Europe for the Mont-Blanc MIS range
- October 29 2019 2019 half year results, revenue for first 9 months
- October 28 2019 Patent issued in the USA for the Mont-Blanc MIS range
- October 18 2019 Reorientation of equity alliance plans and signature of a financing agreement
- October 14 2019 Approval of Mont-Blanc MIS in Japan
- October 3 2019 Report on the October 3, 2019 General Shareholders’ Meeting
- September 30 2019 A €1.3M capital increase for Spineway
- September 23 2019 General Shareholders’ Meeting of 03 October 2019
- September 17 2019 Adjournment of the Ordinary and Extraordinary General Shareholders’ Meeting to be held on 19 september 2019
- September 9 2019 General Shareholders’ Meeting of 19 September 2019
- August 16 2019 Defer of the the General Shareholders’ Meeting of August 16, 2019
- July 25 2019 Minute of the Ordinary and Extraordinary General Shareholders’ Meeting of 24 July 2019
- July 12 2019 Notice of the Ordinary and Extraordinary General Shareholders’ Meeting to be held 24 July 2019
- July 11 2019 Half-year revenue of €2.6M
- July 01 2019 Defer of the the General Shareholders’ Meeting of June 208 2019
- June 24 2019 Annual spinal-surgery convention in Strasbourg and laying the foundation for the joining of Spineway and NCC (Colombia)
- May 24 2019 General Shareholders’ Meeting of 28 June 2019
- May 16 2019 Acquisition confirmed for Latin America and Africa
- May 13 2019 Reduction of share capital
- May 07 2019 Reduction of share capital
- April 29 2019 2018 annual results
- April 16 2019 Subscription of 150 OCEANE
- April 4 2019 Minute of the Ordinary and Extraordinary General Shareholders’ Meeting of 4 April 2019
- March 25 2019 General Shareholders’ Meeting of 4 April 2019
- March 20 2019 Major acquisition planned in Latin America
- March 11 2019 Defer of the the General Shareholders’ Meeting of 8 March 2019
- February 22 2019 General Shareholders’ Meeting of 8 March 2019
- January 31 2019 Strategic Plan NEWWAY 2021
- January 16 2019 2018 revenue of €6.5M
- January 11 2019 2018 liquidity contract annual report
- January 4 2019 Subscription of 100 OCEANE
- December 20 2018 International Symposium in Peru
- November 15 2018 Spineway sets up the governing structure for its US subsidiary
- November 02 2018 Subscription of 100 OCEANE
- September 19 2018 Early redemption of ORNANE
- Otober 24 2018 2018 half year results, revenue for first 9 months at €4,8M, moving forward in the US
- October 18 2018 Marketing of new Mont-Blanc Evo product line authorized in the United States
- September 27 2018 Spineway presents its new Mont-Blanc Evo line at the Eurospine 2018 conference
- September 18 2018 Minute of the Ordinary and Extraordinary General Shareholders’ Meeting of 13 September
- September 19 2018 Subscription of 100 OCEANE
- August 8 2018 Ordinary and Extraordinary General Shareholders’ Meeting of 13 September
- July 11 2018 Revenue for the first half of 2018
- July 10 2018 Liquidity contract half-yearly report
- July 10 2018 Implementation of the new strategic plan and signature of a financing agreement with Alpha Blue Ocean
- June 13 2018 New 2018-2021 strategic plan
- April 26 2018 2017 annual results and activity for the first quarter 2018
- March 28 2018 Amendment liquidity contract (french)
- January 17 2018 2017 was an historic year:9.1M (+97%)
- January 15 2018 1st complex surgery performed in the USA with Spineway's MIS implants
- January 04 2018 Liquidity contract annual report
- December 28 2017 Capital increase of 1.6M€ reserved for Tinavi Medical Technologies
- December 20 2017 Subscription for 200 tranche warrants for Notes with Warrants by the YA II PN, Ltd. investment fund
- December 15 2017 Transfer of the Spineway shares to Euronext Growth Parisé E2 group (public offer)
- December 12 2017 Participation at the BioMed Event December 19 2017 in Paris (French version)
- November 22 2017 Implementation of the SKYWAY 2018 plan
- Novembre 07 2017 Spineway's Board of Directors
- October 23 2017 Sharp increase for 2017 half-year results. 2017 nine-month sales revenue of €7.4M (+125%)
- September 7 2017 Continued expansion in the USA New distributor in Texas
- July 28 2017 Reinforcement of the balance-sheet structure with a reserved issue of Notes with Warrants
- July 18 2017 Confirmed growth Revenue for the first half of 2017: €6M (+146%)
- June 14 2017 Spineway records a new $1M order in the USA
- May 25 2017 Ordinary and Extraordinary General Shareholders' Meeting of 19 June 2017 Access to preparatory documentation
- April 25 2017 2016 Annual results and 1st effects of the SKYWAY 2018 plan
- April 05 2017 Signature of a distribution agreement in Australia 1st Mont-Blanc implants
- March 21 2017 First Mont-Blanc MIS implant in the USA
- March 01 2017 New distribution contract in the USA Appointment of Philippe Laurito as head of the US subsidiary
- January 19 2017 2016 sales revenue, major operational developments and goals for 2018 confirmed
- January 10 2017 Signature of a new distribution agreement in the US
- November 21 2016 Capital increase of €1.4 million Entry of TINAVI Medical Technologies into Spineway's capital
- November 7 2016 Approval of a €1.4M capital increase by a General Meeting of Spineway’s shareholders
- October 24 2016 2016 half year results.
- September 22 2016 Spineway signs a partnership deal with TINAVI Medical Technologie
- September 19 2016 Signature of an important marketing agreement in the USA
- September 12 2016 Deployment continuing in USA, new FDA approvals
- July 19 2016 2016 half year Turn Over
- July 6 2016 success of the Mont Blanc MIS range pre-launching; more of 50 implantations completed
- April 27 2016 2015 annual results.
- April 22 2016 Amendment liquidity contract
- March 7 2016 Mont-Blanc 3D+ : 3 patents delivered in USA and EU.
- February 10 2016 Intensifying business development in USA
- January 13 2016 2015 turn over: + 11%, increased growth confirmed.
- January 4 2016 Transfer of the liquidity contract from ODDO Corporate Finance to PORTZAMPARC Société de Bourse (fr)
- December 16 2015 Intensifying business development in Europe, significant achievements in Switzerland and Denmark.
- December 4 2015 Deployment continuing in Europe. First placement in Belgium and acceleration in Germany (fr)
- October 14 2015 2015 half year results
- September 7 2015 Approval of 3 ranges of products in Australia.
- July 9 2015 2015 half year Turn Over
- June 25 2015 New range Mont-Blanc minimally invasive : A key milestone passed.
- May 26 2015 Update of FDA 510 approval for Mont-Blanc et Blue Mountain ranges
- April 28 2015 Amendment liquidity contract
- April 20 2015 2014 annual results
- April 14 2015 First order for the Mont Blanc Baby in Brazil. Pursuit of the Mont Blanc 3D+ implementation
- March 27 2015 PEA-MPE Eligibility
- February 16 2015 Approval of a third range of products in Brasilia
- January 7 2015 2014 Turn Over: 5,1 M€, solid foundations for 2015
- December 5 2014 Commercial strengthening in India, 2 new distribution contracts
- November 14 2014 Shares buyback
- October 23 2014 2014 half year results
- October 8 2014 Eurospine congress: Mont Blanc 3D+ instrumentation worldwide launch
- July 21 2014 2014 half year Turn Over
- July 8 2014 Capital increase by private placement with accredited investors
- July 1 2014 Acceleration of the deployment in Germany, new exclusive distributor
- June 20 2014 New placement of the Spineway Mont Blanc 3D+ in France and Spineway win a tender with the Montpellier's hospital
- June 12 2014 Updated Offering Circular available
- May 20 2014 First placement of the Spineway Ayers Rock system in USA
- May 7 2014 First placement of the Spineway Mont Blanc 3D+ system in Brazil
- May 2 2014 Amendment liquidity contract
- April 28 2014 2013 Annual accounts
- April 4 2014 First placement of the Spineway Mont Blanc 3D+ system in France
- April 1 2014 PEA-MPE Eligibility
- March 5 2014 EU Sales Manager recruitment
- January 8 2014 2013 Turn Over
- December 18 2013 Amendment liquidity contract
- October 29 2013 2013 half year results
- July 12 2013 2013 half year Turn Over
- April 22 2013 2012 Results
- February 14 2013 Press Release on the first listing on NYSE Alternext Paris
- February 8 2013 Press Release on the private investment of 4.9 M€